HC Wainwright & Co. Maintains Buy on Crinetics Pharmaceuticals, Lowers Price Target to $33
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX), but has lowered the price target from $35 to $33.

August 09, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite a lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Crinetics Pharmaceuticals, indicating continued confidence in the company's potential.
The lowered price target might initially cause some investor concern, potentially leading to short-term price volatility. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100